New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) across PD-L1 expression levels First-line treatment options...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.